Citigroup’s Intellia Therapeutics NTLA Stock Holding History

Citigroup’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,000	Closed	-$158K	–	5810
2023 Q3	$158K	Buy	+5,000	New	+$194K	﹤0.01%	3767
2022 Q4	–	Sell	-25,000	Closed	-$1.4M	–	5899
2022 Q3	$1.4M	Buy	+25,000	New	+$1.55M	﹤0.01%	2451
2020 Q2	–	Sell	-5,600	Closed	-$68K	–	7631
2020 Q1	$68K	Sell	5,600 -20,200	-78%	-$272K	﹤0.01%	5686
2019 Q4	$378K	Buy	25,800 +7,400	+40%	+$103K	﹤0.01%	4670
2019 Q3	$246K	Buy	18,400 +6,900	+60%	+$110K	﹤0.01%	4975
2019 Q2	$188K	Buy	11,500 +8,000	+229%	+$126K	﹤0.01%	5326
2019 Q1	$60K	Sell	3,500 -100	-3%	-$1.49K	﹤0.01%	6187
2018 Q4	$49K	Sell	3,600 -18,500	-84%	-$344K	﹤0.01%	6264
2018 Q3	$633K	Buy	22,100 +10,100	+84%	+$294K	﹤0.01%	3999
2018 Q2	$328K	Buy	12,000 +3,600	+43%	+$87.2K	﹤0.01%	4532
2018 Q1	$177K	Buy	+8,400	New	+$207K	﹤0.01%	5088

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's NTLA Position: Q1 2026 in Review

Citigroup reduced its Intellia Therapeutics (NTLA) stake by 84% in Q1 2026, selling an estimated $2.48M and leaving 36,757 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #3587.

Citigroup first reported a position in NTLA in Q2 2016 and has held it in 39 quarters since. The position peaked at $24.6M in Q1 2022. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Citigroup held 36,757 shares of Intellia Therapeutics worth $471K as of Q1 2026.
Citigroup sold 194,399 Intellia Therapeutics shares in Q1 2026, an estimated $2.48M.
Intellia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3587 holding.
Citigroup first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 39 quarters since.
Citigroup's Intellia Therapeutics position peaked at $24.6M in Q1 2022.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.